Will kinase inhibitors make it as glioblastoma drugs? Review uri icon

Overview

abstract

  • Kinase inhibitors have emerged as effective cancer therapeutics in a variety of human cancers. Glioblastoma (GBM), the most common malignant brain tumor in adults, represents a compelling disease for kinase inhibitor therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Attempts to target the Ras-Phosphatidylinositol 3-kinase (PI3K)-mammalian Target of Rapamycin (mTOR) axis in GBM with first generation receptor tyrosine kinase (RTK) inhibitors and rapalogs have been disappointing. However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors. This chapter reviews common genetic alterations in growth factor signaling pathways in GBM, their validation as therapeutic targets in this disease, and strategies for future clinical development of kinase inhibitors for high grade glioma.

publication date

  • January 1, 2012

Research

keywords

  • Antineoplastic Agents
  • Glioblastoma
  • Mutation
  • Protein Kinase Inhibitors

Identity

PubMed Central ID

  • PMC3784987

Scopus Document Identifier

  • 84871835992

Digital Object Identifier (DOI)

  • 10.1038/nrm3025

PubMed ID

  • 22015553

Additional Document Info

volume

  • 355